JP2010516639A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516639A5
JP2010516639A5 JP2009545828A JP2009545828A JP2010516639A5 JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5 JP 2009545828 A JP2009545828 A JP 2009545828A JP 2009545828 A JP2009545828 A JP 2009545828A JP 2010516639 A5 JP2010516639 A5 JP 2010516639A5
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
tumor
sarcoma
gland
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545828A
Other languages
English (en)
Other versions
JP2010516639A (ja
JP5266253B2 (ja
Filing date
Publication date
Priority claimed from DE102007002715A external-priority patent/DE102007002715A1/de
Application filed filed Critical
Publication of JP2010516639A publication Critical patent/JP2010516639A/ja
Publication of JP2010516639A5 publication Critical patent/JP2010516639A5/ja
Application granted granted Critical
Publication of JP5266253B2 publication Critical patent/JP5266253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

本発明はまた、本発明による化合物の、化学療法による毒性から正常細胞を保護するための使用に、および、タンパク質の誤った折りたたみまたは凝集が主要な原因因子である疾患、例えば、スクレイピー、クロイツフェルト−ヤコブ病、ハンチントン病またはアルツハイマー病(Sittler, Hum. Mol. Genet., 10, 1307, 2001;Tratzelt et al., Proc. Nat. Acad. Sci., 92, 2944, 1995;Winklhofer et al., J. Biol. Chem., 276, 45160, 2001)における使用に関する
A. Kamal et al.によるTrends in Molecular Medicine, Vol. 10 No. 6 June 2004には、HSP90活性化の、特に中枢神経系の疾患および循環器疾患の処置のための、治療的および診断的用途が記載されている。
たがって、HSP90を特異的に阻害、調節および/または調整する小化合物の同定は望ましく、本発明の目的である。
宿主または患者は、任意の哺乳類種に属してよく、例えば、霊長類種、特にヒト;マウス、ラットおよびハムスターを含むげっ歯類;ウサギ、ウマ、ウシ、イヌ、ネコなどである。動物モデルは、実験的研究において興味深く、ここで動物モデルはヒト疾患の処置のためのモデルを提供する。
WO 01/72779には、プリン化合物およびその使用であって、GRP94(HSP90の相同体またはパラログ)誘発性の疾患、例えば腫瘍疾患などの、癌組織が以下からから選択される肉腫または癌腫を含むものの処置のための、前記使用について記載されている:線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病。
本発明は、5−[4−(2−メチルフェニル)−3−ヒドロキシ−4H−1,2,4−トリアゾール−5−イル]−2,4−ジヒドロキシ−N−メチル−N−ブチルベンズアミド、およびその薬学的に使用し得る誘導体、溶媒和物および立体異性体、ならびにそれらの全ての比率での混合物の使用であって、以下の疾患の処置のための、医薬の製造のための前記使用を包含する:腫瘍疾患、例えば、線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病;

Claims (1)

  1. 腫瘍疾患が、線維肉腫、粘液肉腫、脂肪肉腫、軟骨肉腫、骨肉腫、脊索腫、血管肉腫、内皮肉腫、リンパ管肉腫、リンパ管内皮肉腫、膜腫、中皮腫、ユーイング腫瘍、平滑筋肉腫、横紋筋肉腫、大腸癌、膵臓癌、乳癌、卵巣癌、前立腺癌、扁平上皮癌、基底細胞癌、腺癌、汗腺癌、皮脂腺癌、乳頭状癌、乳頭状腺癌、嚢胞腺癌、骨髄癌、気管支原生癌、腎細胞癌、肝細胞癌、胆管癌、絨毛癌、精上皮腫、胎生期癌、ウィルムス腫瘍、頸部癌、精巣腫瘍、肺癌、小細胞肺癌、膀胱癌、上皮癌、神経膠腫、星状細胞腫、髄芽細胞腫、頭蓋咽頭腫、脳室上衣細胞腫、松果体腫、血管芽細胞腫、聴神経腫、乏突起神経膠腫、髄膜腫、黒色腫、神経芽細胞腫、網膜芽細胞腫、白血病、リンパ腫、多発性骨髄腫、ワルデンストレームマクログロブリン血症、およびH鎖病である、請求項5に記載の使用。
JP2009545828A 2007-01-18 2007-12-11 Hsp90阻害剤としてのトリアゾール誘導体 Expired - Fee Related JP5266253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007002715A DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat
DE102007002715.1 2007-01-18
PCT/EP2007/010775 WO2008086857A1 (de) 2007-01-18 2007-12-11 Triazolderivat als hsp 90 inhibitor

Publications (3)

Publication Number Publication Date
JP2010516639A JP2010516639A (ja) 2010-05-20
JP2010516639A5 true JP2010516639A5 (ja) 2011-02-03
JP5266253B2 JP5266253B2 (ja) 2013-08-21

Family

ID=39345628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545828A Expired - Fee Related JP5266253B2 (ja) 2007-01-18 2007-12-11 Hsp90阻害剤としてのトリアゾール誘導体

Country Status (22)

Country Link
US (1) US8816070B2 (ja)
EP (1) EP2102175B1 (ja)
JP (1) JP5266253B2 (ja)
KR (1) KR20090101381A (ja)
CN (1) CN101583605B (ja)
AR (1) AR064951A1 (ja)
AU (1) AU2007344512B2 (ja)
BR (1) BRPI0720956A2 (ja)
CA (1) CA2675737C (ja)
CL (1) CL2008000134A1 (ja)
DE (1) DE102007002715A1 (ja)
EA (1) EA015366B1 (ja)
EC (1) ECSP099586A (ja)
ES (1) ES2455504T3 (ja)
MX (1) MX2009007479A (ja)
MY (1) MY151452A (ja)
NZ (1) NZ579069A (ja)
PE (1) PE20090051A1 (ja)
TW (1) TW200838502A (ja)
UA (1) UA98320C2 (ja)
WO (1) WO2008086857A1 (ja)
ZA (1) ZA200905700B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
SI2490688T1 (sl) * 2009-10-19 2015-01-30 Synta Pharmaceuticals Corp. Kombinirano zdravljenje raka s spojinami - zaviralci HSP90
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE102010024338A1 (de) 2010-06-18 2011-12-22 Merck Patent Gmbh Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid
RS54112B1 (en) * 2010-10-01 2015-12-31 Taisho Pharmaceutical Co. Ltd DERIVAT 1,2,4-TRIAZOLONA
US20130338178A1 (en) * 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN106478531B (zh) * 2015-08-25 2019-06-28 南京华威医药科技集团有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体
IL278698B2 (en) * 2018-05-14 2024-06-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway
CN115006395B (zh) * 2022-04-29 2023-03-14 佛山病原微生物研究院 一种xl888在制备用于抗腺病毒感染的药物中的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1161231A2 (en) 1999-03-12 2001-12-12 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Method of inhibiting a chaperone protein
AU2001247759A1 (en) 2000-03-24 2001-10-08 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
JP2004504356A (ja) 2000-07-20 2004-02-12 メルク エンド カムパニー インコーポレーテッド C型肝炎ウイルスのプロセシングおよび複製の抑制
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
CN1501928A (zh) 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
CN103554042B (zh) * 2004-11-18 2016-08-10 Synta医药公司 调节hsp90活性的三唑化合物
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate

Similar Documents

Publication Publication Date Title
JP2010516639A5 (ja)
JP2010533132A5 (ja)
Sun et al. Natural berberine-hybridized benzimidazoles as novel unique bactericides against Staphylococcus aureus
Dheer et al. Medicinal attributes of 1, 2, 3-triazoles: Current developments
Shafiei et al. History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action
Karakurt et al. Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives
Singh et al. New coumarin-benzotriazole based hybrid molecules as inhibitors of acetylcholinesterase and amyloid aggregation
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
NO20054769D0 (no) Substituerte fenylalkansyrer
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
BR0311291A (pt) Derivados de aminoindazol ativos como inibidores da cinase, processo para sua preparação e composições farmacêuticas compreendendo os mesmos
MA29462B1 (fr) Imidazoquinolines utilises en tant qu'inhibiteurs de kinase lipidique
JP2018534301A (ja) 新規ガラクトシドによるガレクチン阻害剤
Gupta et al. Destabilization potential of phenolics on Aβ fibrils: Mechanistic insights from molecular dynamics simulation
EA200300514A1 (ru) Фармацевтические композиции агониста nmda-рецепторов
CN102333752A (zh) 氧杂二环庚烷与氧杂二环庚烯、它们的制备及应用
Łączkowski et al. Thiazoles with cyclopropyl fragment as antifungal, anticonvulsant, and anti-Toxoplasma gondii agents: synthesis, toxicity evaluation, and molecular docking study
NO20065717L (no) Substituerte N-arylbenzamider og beslektede forbindelser for behandling av amyloidsykdommer og synukleinopatier.
Ahsan et al. Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders
TW200613281A (en) Propane-1,3-dione derivative or salt thereof
Faião-Flores et al. DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1, 4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment
JP5759000B2 (ja) 肝疾患治療の薬物の製造におけるジインドリルメタン及びその前駆体並びにその誘導体の応用
Ozdemir et al. Synthesis, anticonvulsant and antimicrobial activities of some new [1-(2-naphthyl)-2-(pyrazol-1-yl) ethanone] oxime ethers
Brahmbhatt et al. Synthesis, characterization, antibacterial and antioxidant potency of N-substituted-2-sulfanylidene-1, 3-thiazolidin-4-one derivatives and QSAR study
Ye et al. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation